Marian Glynn, PhD, DABT
Drug Development Experience
Marian Glynn, PhD, DABT, is the founder and principal consultant of Tox Clarity. She possesses niche expertise in topical drug product development and has advanced therapies for a range of indications in the fields of dermatology and ophthalmology including wound healing, lice infestation, psoriasis, atopic dermatitis, scleroderma, pruritus, post-herpetic neuralgia, scarring, warts, acne vulgaris, onychomycosis, basal cell carcinoma, actinic keratosis, and rosacea, as well as blepharitis, cataracts, and macular degeneration. Her experience also is deep in the field of hematology, in which she has advanced therapies for hemophilia.
Prior to establishing her independent consultancy, Marian provided nonclinical regulatory strategy and toxicology operations services through Dow Pharmaceutical Sciences, Inc, a then industry leader in topical drug development. Additionally, she supported the Research and Development division of Valeant Pharmaceuticals North America (VPNA) from their acquisition of DPSI through their growth to the largest dermatology company in the United States. There, she trained under the astute guidance of Dr. Linda Mutter, PhD, DABT.
Marian is certified in general toxicology by the American Board of Toxicology (DABT). She earned her doctorate of philosophy (PhD) with the Pharmacology and Toxicology (PTX) Graduate Group at the University of California, Davis (UCD) in the laboratory of Dr. A. Kimberley McAllister. She earned her Bachelor of Sciences (BS) cum laude at Duke University.